Penetrance of PD in Glucocerebrosidase Gene Mutation Carriers
Citation Manager Formats
Make Comment
See Comments

In their study, Anheim et al.1 attempt to estimate the penetrance of Parkinson disease (PD) among GBA mutation carriers by studying familial PD. They determined that the PD penetrance in GBA carriers was approximately 30% at age 80 under a dominant model, and concluded that families could be counseled that GBA can be considered a dominant causal gene with reduced penetrance. We are troubled by this conclusion.
While GBA is an important risk factor for parkinsonism,2 the majority of patients with Gaucher disease and GBA mutation carriers never develop PD.3 Data from a large Gaucher Registry demonstrated that among patients homozygous for GBA mutations, the probability of developing PD before age 70 was 5%–7%, and 9%–12% before age 80.4 In the study by Anheim et al., ascertainment bias could be inflating the penetrance assessment. But our concern actually runs deeper, and relates to attaching labels to modes of inheritance in such instances.
It is becoming increasingly clear that the boundaries between what were once considered “simple” Mendelian disorders and complex disorders are often quite blurred. In a 2000 editorial, Drs. Dipple and McCabe5 stated: “There is no obvious clear distinction between simple Mendelian and complex traits: genetic diseases represent a continuum with diminishing influence from a single primary gene influenced by modifier genes, to increasingly shared influence by multiple genes.” Thus, categorizing GBA-associated parkinsonism as a Mendelian trait may be unnecessary and confusing.
We fear that a health care provider might communicate a dominant mode of inheritance without fully understanding the complexity of the situation. This may prompt unnecessary anxiety in a patient population already at risk for a recessive disorder.
- Copyright © 2012 by AAN Enterprises, Inc.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriersM. Anheim, A. Elbaz, S. Lesage et al.Neurology, January 25, 2012 -
Articles
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson diseaseL. N. Clark, B. M. Ross, Y. Wang et al.Neurology, September 17, 2007 -
Brief Communications
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian populationM. Toft, L. Pielsticker, O. A. Ross et al.Neurology, February 13, 2006 -
Brief Communications
Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype–genotype correlationJudith Aharon-Peretz, Samih Badarny, Hanna Rosenbaum et al.Neurology, September 07, 2005